DNA blood test may spot nasopharyngeal cancer earlier than current methods

NCT ID NCT06763289

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

Researchers are testing whether a blood test that looks at DNA methylation patterns can find nasopharyngeal carcinoma earlier and more accurately than the standard Epstein-Barr virus (EBV) tests. The study will compare the new multi-omics model with EBV DNA quantification and two antibody tests in 700 adults aged 40 to 74, some with cancer and some without. The goal is to see if the DNA-based approach reduces false negatives and false positives, improving early detection and avoiding unnecessary procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood-based multi-omics screening model using DNA methylation and fragmentome analysis, compared with standard EBV DNA quantification and EBNA1-IgA/VCA-IgA antibody tests
What this could lead to
If successful, this could lead to a more accurate blood test for early nasopharyngeal carcinoma, reducing false negatives and false positives compared to current EBV-based methods.
What could go wrong
This is a comparison study, not a treatment trial, so it won't directly improve outcomes. The new model may not outperform existing tests in real-world settings, and results depend on the specific population studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Confirmed cancers or individuals without confirmed cancer will be invited to participate in this case-control study by a designated consenting professional.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Case Arm Participants: 1. 40-74 years old 2. Clinically and/or pathologically diagnosed cancer 3. No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc. 4. Able to provide a written informed consent and willing to comply with all part of the protocol procedures Exclusion Criteria for Case Arm Participants: 1. Pregnancy or lactating women 2. Known prior or current diagnosis of other types of malignancies comorbidities 3. Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen 4. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant 5. Recipients of blood transfusion within 30 days prior to screen 6. Recipients of therapy in past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide 7. Unsuitable for this trial determined by the researchers Inclusion Criteria for Control Arm Participants: 1. 40-74 years old 2. Without confirmed cancer diagnosis 3. Able to provide a written informed consent and willing to comply with all part of the protocol procedures Exclusion Criteria for Control Arm Participants: 1. Pregnancy or lactating women 2. Known prior or current diagnosis of other types of malignancies comorbidities 3. Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen 4. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant 5. Recipients of blood transfusion within 30 days prior to screen 6. Recipients of therapy in the past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide 7. Unsuitable for this trial determined by the researchers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.